CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER:

22-278

MICROBIOLOGY REVIEW(S)

Product Quality Microbiology Review

24-JULY-2008

NDA: 22-278/N-000
22-278/N-000-BI

Drug Product Name
Proprietary: MembraneBlue
Non-proprietary: 0.15% Trypan Blue Ophthalmic Solution
Drug Product Priority Classification: Priority

Review Number: 1

Dates of Submission(s) Covered by this Review

Letter	Stamp	Review Request	Assigned to Reviewer
10/1/07	10/4/07	10/29/07	10/31/07
6/25/08	6/30/08	7/2/08	7/2/08

Submission History (for amendments only): Not applicable

Applicant/Sponsor
Name: Dutch Ophthalmic Research Center International bv
Address: Scheijdelveweg 2
3214VN Zuidland
The Netherlands

Representative: Frank M. Ruseler
Telephone: +31 181 458080

Name of Reviewer: Stephen E. Langille, Ph.D.

Conclusion: Recommended for approval

Product Quality Microbiology Data Sheet

A. 1. **TYPE OF SUBMISSION:** Original NDA – Orphan Drug Product

2. **SUBMISSION PROVIDES FOR:** Sterility assurance information

3. **MANUFACTURING SITE:**

_____ b(4)

4. **DOSAGE FORM, ROUTE OF ADMINISTRATION AND STRENGTH/POTENCY:**

- Sterile Solution
- Intra-ocular injection
- 0.15% trypan blue
- Pre-packaged syringes
- 0.5 mL/syringe

5. **METHOD(S) OF STERILIZATION:** _____ b(4)

6. **PHARMACOLOGICAL CATEGORY:** Ophthalmic posterior membrane staining

B. **SUPPORTING/RELATED DOCUMENTS:** NDA 21-670/SCM-002 seeks approval for the manufacture of a product called VisionBlue™ at the _____ facility. VisionBlue™ has a composition, packaging and manufacturing process that is very similar to MembraneBlue™. NDA 21-670/SCM-002 was found to be approvable pending the resolution of product quality microbiology deficiencies. b(4)

C. **REMARKS:** The NDA was provided as a paper submission (black binder) and was not arranged in CTD format. An Initial Quality Assessment was entered in DFS on November 28, 2007. An information request for product quality microbiology issues was sent to the applicant on June 4, 2008. The applicant responded with a document dated June 25, 2008. Additional information was requested by the Agency and provided by the applicant via e-mail on July 17, 2008. An official copy of this information will be submitted to the agency on July 28, 2008.

filename: N022278R1.doc

Executive Summary

I. Recommendations

A. Recommendation on Approvability -
NDA 22-278 is recommended for approval from the standpoint of product quality microbiology.

B. Recommendations on Phase 4 Commitments and/or Agreements, if Approvable -
Not applicable

II. Summary of Microbiology Assessments

A. Brief Description of the Manufacturing Processes that relate to Product Quality Microbiology -
The drug product is packaged in a pre-filled syringe. Both the contents of the syringe and the outside of the syringe are labeled as sterile for use in surgical settings.

B. Brief Description of Microbiology Deficiencies -
No deficiencies were identified based upon the information provided.

C. Assessment of Risk Due to Microbiology Deficiencies -
Not applicable

III. Administrative

A. Reviewer's Signature _____

B. Endorsement Block
James McVey – Team Leader

C. CC Block
N/A

5 Page(s) Withheld

√ § 552(b)(4) Trade Secret / Confidential

_____ § 552(b)(4) Draft Labeling

_____ § 552(b)(5) Deliberative Process

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

Stephen Langille
7/28/2008 08:35:27 AM
MICROBIOLOGIST
Membrane Blue - terminally sterilized injectable.

James McVey
7/28/2008 09:34:55 AM
MICROBIOLOGIST
I concur.